11 companies in Japan Voluntary collection of ranitidine hydrochloride for treatment of stomach ulcers, etc.
Eleven manufacturers that manufacture and sell drugs have begun voluntary collections because ranitidine hydrochloride, a treatment for stomach ulcers, may contain carcinogenic substances. According to the Ministry of Health, Labor and Welfare, there have been no reports of health damage so far.
Ranitidine hydrochloride is a treatment for stomach and duodenal ulcers, and according to the Ministry of Health, Labor and Welfare, it has been found that this drug may contain a carcinogen called NDMA.
For this reason, a total of 11 companies in Japan that manufacture and sell drugs have started voluntary collection.
The 11 companies are Takeda Teva Pharma, ▼ Kobayashi Chemical, ▼ Sawai Pharmaceutical, ▼ Tsuruhara Pharmaceutical, ▼ Towa Pharmaceutical, ▼ Nipro, ▼ Mylan Pharmaceutical, ▼ Nippon Generic, ▼ Nikko, ▼ Yoshindo, ▼ GlaxoSmithKline .
With regard to ranitidine hydrochloride, there are reports that carcinogenic substances have been detected in overseas countries such as the United States and Europe, and the Ministry of Health, Labor and Welfare requested 11 companies to analyze the ingredients last month. A small amount of carcinogen was detected.
According to the Ministry of Health, Labor and Welfare, there are no reports of health damage caused by taking the medicine so far.